Sorafenib is the standard treatment for patients with hepatocellular carcinoma (HCC) with advanced stage disease. Although its effectiveness has been demonstrated by randomized clinical trials and confirmed by field practice studies, reliable markers predicting therapeutic response have not yet been identified. Like other tyrosine kinase inhibitors, treatment with sorafenib is burdened by the development of adverse effects, the most frequent being cutaneous toxicity, diarrhoea, arterial hypertension and fatigue. In recent years, several studies have analysed the correlation between off-target effects and sorafenib efficacy in patients with HCC. In this review, an overview of the studies assessing the prognostic significance of sorafenib-related adverse events is provided.

Granito, A., Marinelli, S., Negrini, G., Menetti, S., Benevento, F., Bolondi, L. (2016). Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 9(2), 240-249 [10.1177/1756283X15618129].

Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib

GRANITO, ALESSANDRO;MARINELLI, SARA;NEGRINI, GIULIA;BOLONDI, LUIGI
2016

Abstract

Sorafenib is the standard treatment for patients with hepatocellular carcinoma (HCC) with advanced stage disease. Although its effectiveness has been demonstrated by randomized clinical trials and confirmed by field practice studies, reliable markers predicting therapeutic response have not yet been identified. Like other tyrosine kinase inhibitors, treatment with sorafenib is burdened by the development of adverse effects, the most frequent being cutaneous toxicity, diarrhoea, arterial hypertension and fatigue. In recent years, several studies have analysed the correlation between off-target effects and sorafenib efficacy in patients with HCC. In this review, an overview of the studies assessing the prognostic significance of sorafenib-related adverse events is provided.
2016
Granito, A., Marinelli, S., Negrini, G., Menetti, S., Benevento, F., Bolondi, L. (2016). Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 9(2), 240-249 [10.1177/1756283X15618129].
Granito, A; Marinelli, S; Negrini, G; Menetti, S; Benevento, F; Bolondi, L
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/542713
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 41
  • Scopus 71
  • ???jsp.display-item.citation.isi??? 74
social impact